<div>
  <ul>
    <li>
      <p>
        PharmaDrug, a Toronto-based specialty pharmaceutical company, has entered a definitive agreement to acquire SecureDose Synthetics, a synthetic formulation company in an all-share transaction to strengthen its R&amp;D capabilities. SecureDose will become a wholly-owned subsidiary of PharmaDrug upon the completion of the acquisition, which is expected to close in early November 2023, subject to board and regulatory approvals.
      </p>
    </li>
    <li>
      <p>
        Under the terms of the agreement, each SecureDose share will be exchanged for one PharmaDrug share. Furthermore, the SecureDose warrants and finder warrants will enable holders to acquire PharmaDrug shares at a price of USD 0.10 before September 22, 2025. The holders of SecureDose securities before the acquisition will collectively own approximately 38% of PharmaDrug (or 43% when including the conversion of warrants), and the control of PharmaDrug would not change.
      </p>
    </li>
    <li>
      <p>
        <b>Analyst QuickTake: </b>
        As M&amp;As in the psychedelic industry persist, this would be PharmaDrug&rsquo;s third acquisition. It acquired 
        <a href="https://www.newsfilecorp.com/release/57885/Pharmadrug-Inc.-Completes-Acquisition-of-Super-Smart-with-a-New-Added-Focus-on-the-Psychedelic-Market">
          Super Smart
        </a>
        , which focuses on the development of psychedelic compounds in June 2020, and 
        <a href="https://www.biospace.com/article/pharmadrug-completes-acquisition-of-sairiyo-therapeutics-inc-/">
          Sairiyo Therapeutics
        </a>
        , which focuses on developing novel treatments for neurological disorders in February 2021. The acquisition of SecureDose will complement PharmaDrug's growth strategy to advance its product pipeline by adding the capability to develop its own formulations, potentially leading to shorter time frames for commercialization and revenue opportunities.
      </p>
    </li>
  </ul>
  <p>
  </p>
</div>


<div>
  <p>
    <a href="https://www.newsfilecorp.com/release/185395">
      Press release
    </a>
  </p>
  <p>
  </p>
</div>


Psychedelic Medicine

ANALYST_QUICK_TAKE

DISRUPTOR_PRESENT

<div>
 <ul>
  <li><p>PharmaDrug, a Toronto-based specialty pharmaceutical company, is acquiring SecureDose Synthetics, a synthetic formulation company, in an all-share transaction to enhance its R&amp;D capabilities. Upon completion of the acquisition, SecureDose will be a wholly-owned subsidiary of PharmaDrug. The deal is expected to close in early November 2023, pending board and regulatory approvals.</p></li>
  <li><p>According to the agreement, each SecureDose share will be exchanged for one PharmaDrug share. Holders of SecureDose securities will also have the opportunity to acquire PharmaDrug shares at a price of USD 0.10 before September 22, 2025, through SecureDose warrants and finder warrants. The current holders will collectively own around 38% of PharmaDrug (or 43% with warrant conversion), with no change in control of PharmaDrug.</p></li>
 </ul>
</div> <p><b>Analyst QuickTake: </b> As M&amp;As in the psychedelic industry persist, this would be PharmaDrug’s third acquisition. It acquired <a href="https://www.newsfilecorp.com/release/57885/Pharmadrug-Inc.-Completes-Acquisition-of-Super-Smart-with-a-New-Added-Focus-on-the-Psychedelic-Market"> Super Smart </a> , which focuses on the development of psychedelic compounds in June 2020, and <a href="https://www.biospace.com/article/pharmadrug-completes-acquisition-of-sairiyo-therapeutics-inc-/"> Sairiyo Therapeutics </a> , which focuses on developing novel treatments for neurological disorders in February 2021. The acquisition of SecureDose will complement PharmaDrug's growth strategy to advance its product pipeline by adding the capability to develop its own formulations, potentially leading to shorter time frames for commercialization and revenue opportunities.</p>

PharmaDrug to acquire SecureDose Synthetics in all-share transaction

Toronto-based specialty pharmaceutical company, PharmaDrug, has announced the appointment of Robert J. Steen as its new CEO, effective from September 6, 2023. Steen will replace the current CEO, Daniel Cohen, who will continue to advise the company during the transition. The company also revealed that Michael Forbes has resigned from the board of directors. Steen, who has an MBA and a background in entrepreneurship, previously founded Trafalgar Addiction Treatment Centres before it was acquired by a conglomerate in 2022.

All Updates

PharmaDrug to acquire SecureDose Synthetics in all-share transaction

PharmaDrug appoints Robert J. Steen as new CEO

PharmaDrug partners with PharmaTher to develop DMT Transdermal patch

PharmaDrug commences trading on the OTCQB market